TB-500

TB-500 is a synthetic fragment of thymosin beta-4 that promotes cell migration, angiogenesis, and tissue repair by upregulating actin. It is under FDA reclassification review, is widely used in veterinary medicine, and is most commonly studied in animal models of wound healing and cardiac recovery.

TB-500 is the synthetic research form of a specific actin-binding fragment of thymosin beta-4 (Tβ4), the 43-amino-acid peptide originally isolated from calf thymus tissue. The full Tβ4 molecule is the most abundant sequestered actin monomer-binding peptide in the cytoplasm of nearly all mammalian non-muscle cells, present at concentrations of 300-500 µM. TB-500 corresponds to the 17-23 amino acid region of Tβ4 (the tetrapeptide Ac-SDKP or the LKKTETQ sequence depending on the source literature), which retains the primary biological activities of the full protein: actin sequestration, cell migration promotion, anti-inflammatory action, and angiogenesis stimulation. In research contexts, TB-500 and Tβ4 are often used interchangeably, though they are technically distinct — the full Tβ4 protein also contains domains involved in cardiac progenitor activation that TB-500's shorter sequence partially captures.

TB-500 has attracted significant research attention across multiple tissue-repair contexts because its mechanism — regulating the pool of unpolymerized actin available for cytoskeletal reorganization — underpins the basic biology of wound healing, cell migration, and tissue remodeling. Every cell that moves toward a wound, lays down new extracellular matrix, or forms a new capillary does so through actin filament polymerization at the leading edge. By sequestering G-actin (globular, unpolymerized actin) in a readily mobilizable reservoir, Tβ4 and TB-500 enable faster, more coordinated cell migration responses at sites of injury. This makes TB-500 a potential systemic accelerant for healing across diverse tissue types — skin, muscle, tendon, ligament, and heart.

In the sports and biohacking communities, TB-500 is primarily used for injury recovery: tendon and ligament injuries, muscle tears, joint inflammation, and chronic injuries that have failed to resolve through conventional rehabilitation. Its systemic mechanism — it acts through the bloodstream rather than at a local injection site — is a distinguishing feature from BPC-157, which is often applied locally. TB-500 is also frequently stacked with BPC-157 in a combination sometimes called the "Wolverine stack," leveraging BPC-157's local tissue and GI repair mechanisms alongside TB-500's systemic cellular mobilization.

TB-500's parent compound, full-length thymosin beta-4, has reached clinical trials through RegeneRx Biopharmaceuticals for wound healing and cardiac applications. Phase II data in dry-eye disease showed significant improvement in corneal epithelial cell migration and reduced inflammation, and preclinical heart attack data prompted a Phase I safety study. TB-500 as a synthetic fragment is not FDA-approved, is classified as a research chemical, and is banned by WADA. Animal studies form the bulk of the efficacy evidence, with human data limited to use of the full Tβ4 protein in sponsor-run trials.

TB-500's primary molecular action is binding to G-actin (monomeric, unpolymerized actin) in a 1:1 stoichiometric ratio. G-actin constitutes approximately 50-70% of the total cellular actin pool in resting cells; Tβ4 sequesters a significant fraction of this pool, preventing premature polymerization into F-actin (filamentous actin) while keeping it available for rapid deployment. When a cell receives a migration signal — whether from a chemokine gradient, growth factor, or damage-associated molecular pattern — localized activation of actin nucleators (Arp2/3 complex, formins) at the cell's leading edge creates a sink for G-actin monomers. Tβ4 and TB-500 release their sequestered actin into this sink, fueling the explosive growth of branched actin networks that push the plasma membrane forward. This dramatically accelerates cell migration speed and persistence compared to cells depleted of Tβ4.

Downstream of actin regulation, TB-500 promotes angiogenesis through upregulation of vascular endothelial growth factor (VEGF) and promotes the migration of endothelial cells, keratinocytes, and fibroblasts into wound sites. Studies in thymosin beta-4-treated dermal wound models show increased collagen deposition and more organized extracellular matrix architecture compared to controls. The peptide also modulates inflammatory signaling: studies demonstrate down-regulation of NF-κB-driven pro-inflammatory cytokines (TNF-α, IL-1β) and up-regulation of anti-inflammatory mediators, which reduces the chronic inflammatory state that impairs healing in diabetic or aged tissue.

The cardiac repair literature has revealed an additional mechanism not directly tied to actin sequestration. The Bock-Marquette et al. Nature (2004) study demonstrated that Tβ4 activates integrin-linked kinase (ILK), which promotes the survival and migration of epicardium-derived cardiac progenitor cells in the post-infarct heart. This ILK pathway activation leads to increased expression of anti-apoptotic proteins (Akt, surviving) in cardiomyocytes adjacent to the infarct zone, reducing the extent of programmed cell death. Subsequent coronary artery ligation studies in mice showed that Tβ4 treatment reduced infarct size by approximately 25%, preserved ejection fraction, and stimulated formation of new coronary microvessels in the peri-infarct region.

TB-500's systemic action — it distributes through the bloodstream after subcutaneous injection and reaches injured tissue via the circulation — distinguishes it pharmacologically from locally-acting repair peptides. Because actin-sequestering capacity and cell migration signaling are relevant at every site of active tissue damage simultaneously, TB-500 can in principle accelerate healing across multiple concurrent injury sites. This systemic reach is the biological basis for its use in loading-dose protocols: higher initial doses are used to rapidly establish elevated systemic Tβ4 concentrations, followed by lower maintenance doses once tissue repair is underway.

The foundational animal wound healing study for thymosin beta-4 (Tβ4) was published by Philp et al. in the Journal of Investigative Dermatology (2003), demonstrating that topical Tβ4 in gel or solution form accelerated full-thickness dermal wound closure in three mouse models: normal, steroid-impaired, and db/db diabetic mice. In the diabetic model — where impaired wound healing has multiple compounding mechanisms — Tβ4-treated wounds closed 42% faster than vehicle controls by day 7, with histological analysis showing increased keratinocyte migration, greater collagen deposition, and enhanced neovascularization at wound edges. The study established that the active domain was the 17-23 amino acid actin-binding fragment, precisely the sequence corresponding to TB-500.

The cardiac repair literature began with the landmark Bock-Marquette et al. study in Nature (2004), which showed that Tβ4 promoted cardiomyocyte survival and activated epicardium-derived cardiac progenitor cell migration after experimental myocardial infarction in mice. Animals receiving Tβ4 had significantly better post-infarction ejection fraction, reduced scar size, and enhanced coronary microvascular density. These findings were further developed by Smart et al. (Nature, 2007), who demonstrated that Tβ4 priming before ischemic injury activated a normally dormant pool of epicardial progenitor cells capable of differentiating into new cardiomyocytes and vascular smooth muscle cells — suggesting a regenerative mechanism beyond cell survival. Infarct size reduction in these animal studies was in the range of 20-30% with treatment versus controls.

RegeneRx Biopharmaceuticals translated these animal findings into Phase I and II clinical trials with full-length Tβ4. A Phase II trial for neurotrophic keratopathy (corneal wounds) showed that topical Tβ4 accelerated corneal healing with a favorable safety profile. A Phase I trial in chronic sternal wound patients established safety. These human safety data apply to full-length Tβ4, not directly to the synthetic TB-500 fragment, but they support the broader safety profile of the Tβ4 biology.

Skeletal muscle repair data come from studies of Tβ4 in dystrophic mdx mice (a Duchenne muscular dystrophy model) and cardiotoxin-injured muscle models, where Tβ4 accelerated satellite cell recruitment, reduced fibrotic scar deposition, and improved functional contractile recovery. Angiogenesis studies in ischemic hindlimb mouse models demonstrated that Tβ4 increased collateral vessel formation and restored limb perfusion to levels significantly above controls. A 2021 Frontiers in Endocrinology review catalogued over 30 animal studies across tissue types, consistently showing Tβ4 accelerating repair and reducing inflammatory markers.

The critical caveat for TB-500 specifically (as distinct from full Tβ4) is that no controlled human clinical trials have been published using the synthetic peptide fragment. Extrapolation from Tβ4 trials to TB-500 is mechanistically reasonable but not formally validated in humans. Loading-dose protocols circulating in the biohacking community are derived from veterinary studies and extrapolated from animal research, not from human pharmacokinetic trials. TB-500 is banned by WADA under Section S2 (Other Anabolic Agents and Peptide Hormones) and is not FDA-approved for human use.[1][2][3][4][5][6]

Peptides commonly paired with TB-500 for synergistic effects.